L
Louise Ritz
Researcher at National Institutes of Health
Publications - 45
Citations - 14220
Louise Ritz is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Risperidone & Randomized controlled trial. The author has an hindex of 36, co-authored 45 publications receiving 13267 citations. Previous affiliations of Louise Ritz include University of Pittsburgh & Harvard University.
Papers
More filters
Journal ArticleDOI
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Madhukar H. Trivedi,A. John Rush,Stephen R. Wisniewski,Andrew A. Nierenberg,Diane Warden,Louise Ritz,Grayson Norquist,Robert H Howland,Barry D. Lebowitz,Patrick J. McGrath,Kathy Shores-Wilson,Melanie M. Biggs,Goundappa K. Balasubramani,Maurizio Fava +13 more
TL;DR: The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Journal ArticleDOI
Risperidone in Children with Autism and Serious Behavioral Problems
James T. McCracken,James J. McGough,Bhavik Shah,Pegeen Cronin,Daniel Hong,Michael G. Aman,L. Eugene Arnold,Ronald L. Lindsay,Patricia L. Nash,Jill A. Hollway,Christopher J. McDougle,David J. Posey,Naomi B. Swiezy,Arlene E. Kohn,Lawrence Scahill,Andrés Martin,Kathleen Koenig,Fred R. Volkmar,Deirdre H. Carroll,Allison Lancor,Allison Lancor,Elaine Tierney,Jaswinder K. Ghuman,N. González,Marco A. Grados,Benedetto Vitiello,Louise Ritz,Mark Davies,James Robinson,Donald J. McMahon +29 more
TL;DR: Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder and the benefit was maintained at six months.
Journal ArticleDOI
Sequenced treatment alternatives to relieve depression (STAR * D): rationale and design
A. John Rush,Maurizio Fava,Stephen R. Wisniewski,Philip W. Lavori,Madhukar H. Trivedi,Harold A. Sackeim,Michael E. Thase,Andrew A. Nierenberg,Frederic M. Quitkin,T. Michael Kashner,David J. Kupfer,Jerrold F. Rosenbaum,Jonathan E. Alpert,Jonathan W. Stewart,Patrick J. McGrath,Melanie M. Biggs,Kathy Shores-Wilson,Barry D. Lebowitz,Louise Ritz,George Niederehe +19 more
TL;DR: STAR*D as discussed by the authors is a multisite, prospective, randomized, multistep clinical trial of outpatients with nonpsychotic major depressive disorder, which compared various treatment options for those who do not attain a satisfactory response with citalopram, a selective serotonin reuptake inhibitor antidepressant.
Journal ArticleDOI
Medication Augmentation after the Failure of Ssris for Depression
Madhukar H. Trivedi,Maurizio Fava,Stephen R. Wisniewski,Michael E. Thase,Frederick M. Quitkin,Diane Warden,Louise Ritz,Andrew A. Nierenberg,Barry D. Lebowitz,Melanie M. Biggs,James F. Luther,Kathy Shores-Wilson,A. John Rush +12 more
TL;DR: Augmentation of citalopram with either sustained-release bupropion or buspirone appears to be useful in actual clinical settings, including a greater reduction in the number and severity of symptoms and fewer side effects and adverse events.
Journal ArticleDOI
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Jonathan W. Stewart,Andrew A. Nierenberg,Michael E. Thase,Louise Ritz,Melanie M. Biggs,Diane Warden,James F. Luther,Kathy Shores-Wilson,George Niederehe,Maurizio Fava +12 more
TL;DR: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant, suggesting any one of the medications in the study provided a reasonable second-step choice for patients with depression.